Core Viewpoint - TATA Health (01255.HK) reported a significant increase in revenue for the fiscal year ending December 31, 2023, primarily driven by growth in its footwear business, despite incurring a substantial loss [1] Financial Performance - The company's revenue for the year was approximately HKD 208 million, representing a year-on-year increase of about 43.5% [1] - The pre-tax loss for the year was approximately HKD 35.4 million, compared to a pre-tax profit of approximately HKD 2.5 million for the fiscal year ending December 31, 2022 [1] - Basic and diluted loss per share was HKD 0.13 [1] Business Segment Analysis - The footwear business accounted for over 98% of the company's revenue, with annual sales increasing by 43.8% compared to the previous year [1] - The company plans to focus more on diversifying its footwear products, exploring potential business collaborations, and introducing new brands with growth potential and high profit margins [1] Market Comparison - In comparison, another Hong Kong-based company, 德诚集团, reported revenue that remained flat year-on-year and will continue to focus on developing its financing advisory business and exploring new market opportunities, such as Singapore [1]
TATA健康(01255.HK)2023年收入约2.08亿港元 同比增加约43.5%